Literature DB >> 9887971

Myosin phosphatase: subunits and interactions.

D J Hartshorne1.   

Abstract

Myosin phosphorylation is an important mechanism in regulating contractile activity of smooth muscle. The level of myosin phosphorylation depends on the balance of two enzymes, myosin light chain kinase and myosin phosphatase. Recently it has been discovered that myosin phosphatase can be regulated and this renewed interest in characterization of the phosphatase. It is suggested that the myosin phosphatase is composed of three subunits: a catalytic subunit of type 1 phosphatase (delta isoform; PP1c delta); and two non-catalytic subunits, large and small (M20). The large subunit is thought to be a targeting subunit and is termed myosin phosphatase target subunit (MYPT). There are several isoforms of MYPT and two genes have been identified on human chromosomes 1 and 12. A dominant feature of MYPT is a series of ankyrin repeats at the N-terminal end of the molecule and these may be involved in binding to the catalytic subunit and to substrate, phosphorylated myosin. In addition, at the N-terminal fringe of the ankyrin motifs is a consensus PP1c binding motif. The function of the M20 subunit is not established but is known to bind to the C-terminal end of MYPT. Various interactions between subunits that might be relevant for the regulation of phosphatase activity are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9887971     DOI: 10.1046/j.1365-201X.1998.00447.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  37 in total

1.  Distinct tissue distributions and subcellular localizations of differently phosphorylated forms of the myosin regulatory light chain in Drosophila.

Authors:  Liang Zhang; Robert E Ward
Journal:  Gene Expr Patterns       Date:  2010-10-30       Impact factor: 1.224

2.  Pharmacology and thermosensitivity of the dartos muscle isolated from rat scrotum.

Authors:  Alan Gibson; Adetokunbo Akinrinsola; Tejesh Patel; Arijit Ray; John Tucker; Ian McFadzean
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

3.  p116Rip targets myosin phosphatase to the actin cytoskeleton and is essential for RhoA/ROCK-regulated neuritogenesis.

Authors:  Jacqueline Mulder; Aafke Ariaens; Dick van den Boomen; Wouter H Moolenaar
Journal:  Mol Biol Cell       Date:  2004-10-06       Impact factor: 4.138

4.  Effect of elevated intracellular cAMP levels on actomyosin contraction in bovine trabecular meshwork cells.

Authors:  Charanya Ramachandran; Rajkumar V Patil; Najam A Sharif; Sangly P Srinivas
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-18       Impact factor: 4.799

5.  Exercise-induced inhibition of angiotensin II vasoconstriction in human thigh muscle.

Authors:  R Matthew Brothers; Mads L Haslund; D Walter Wray; Peter B Raven; Mikael Sander
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

Review 6.  Cellular and molecular mechanisms regulating vascular tone. Part 2: regulatory mechanisms modulating Ca2+ mobilization and/or myofilament Ca2+ sensitivity in vascular smooth muscle cells.

Authors:  Takashi Akata
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

Review 7.  Morphogenic signaling in neurons via neurotransmitter receptors and small GTPases.

Authors:  Evgeni Ponimaskin; Tatyana Voyno-Yasenetskaya; Diethelm W Richter; Melitta Schachner; Alexander Dityatev
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

Review 8.  Rho kinase (ROCK) inhibitors.

Authors:  James K Liao; Minoru Seto; Kensuke Noma
Journal:  J Cardiovasc Pharmacol       Date:  2007-07       Impact factor: 3.105

Review 9.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

10.  The pro-apoptotic protein Par-4 facilitates vascular contractility by cytoskeletal targeting of ZIPK.

Authors:  Susanne Vetterkind; Kathleen G Morgan
Journal:  J Cell Mol Med       Date:  2008-05-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.